![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » ABBOTT LABS STILL HAS 'CONSIDERABLE' UPSIDE POTENTIAL
ABBOTT LABS STILL HAS 'CONSIDERABLE' UPSIDE POTENTIAL
November 29, 2005
Banc of America Securities reiterated a "buy" rating on Abbott Laboratories and lowered the target price to $46 from $49. The research firm said "there is still much to like" about Abbott, and that shares of the healthcare-products company have "considerable" upside potential.
Forbes (http://www.forbes.com/2005/11/28/abbott-labs-earnings-1128markets14_print.html)
KEYWORDS FDAnews Device Daily Bulletin
Upcoming Events
-
21Oct